$11 billion drugmaker Mylan and US drug giant Pfizer are teaming up to reshape Mylan’s business. 3 tough questions from Wall Street analyst show the challenging road ahead.

Three tough questions from Wall Street analysts on a Monday conference call show why the spinoff could face an uphill battle.

A major deal announced on Monday will combine generic drugmaker Mylan with a unit of Pfizer that makes off-patent products like Viagra., best known for making the EpiPen allergy shot. Mylan's shares have lost almost half their value over the past year, though they surged 14% on Monday after the deal was announced. Pfizer's stock fell 2%.

المملكة العربية السعودية أحدث الأخبار, المملكة العربية السعودية عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Fewer investors have a 'fear of missing out,' so it may be time to buckle up, market bull suggestsOppenheimer Asset Management's John Stoltzfus expects wave of volatility to pressure stocks due to uncertainty. FuturesNow ohh it's going to be a a good dump for sure!
مصدر: CNBC - 🏆 12. / 72 اقرأ أكثر »